The U.S. District Court for the Southern District of California has granted a request by Amylin Pharmaceuticals for a temporary restraining order related to litigation involving its diabetes collaboration agreement with Eli Lilly.
"We are disappointed with the court's decision to grant a temporary restraining order," said Robert A. Armitage, senior vice president and general counsel for Lilly. "We have complied with our contractual obligations under our agreements with Amylin in a manner fully consistent with all applicable laws. We believe that Amylin's allegations against Lilly are entirely without merit and we fully expect to prevail in this litigation."
Earlier this month, the San Diego-based Amylin filed a suit against Lilly alleging that Lilly breached alliance agreements and is participating in “anti-competitive activity” regarding the commercialization of exenatide (Byetta), a glucagon-like peptide-1 receptor agonist approved to treat type 2 diabetes.
The Indianapolis-based Lilly said it is taking the "appropriate steps" to comply with the court's order, including as it relates to the activities of its salesforce, while working to mitigate the impact of any temporary modifications to its diabetes business.